Theravance Biopharma Inc
Company Profile
Business description
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Contact
C/O Theravance Biopharma US, LLC
901 Gateway Boulevard
South San FranciscoCA94080
USAT: +1 650 808-6000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
90
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.30 | 31.20 | 0.35% |
| CAC 40 | 8,021.35 | 45.23 | 0.57% |
| DAX 40 | 24,334.00 | 342.73 | 1.43% |
| Dow JONES (US) | 48,941.90 | 557.37 | -1.13% |
| FTSE 100 | 10,222.08 | 141.85 | -1.37% |
| HKSE | 25,898.61 | 197.27 | -0.76% |
| NASDAQ | 25,067.80 | 46.64 | -0.19% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,035.70 | 61.98 | -0.47% |
| S&P 500 | 7,200.75 | 29.37 | -0.41% |
| S&P/ASX 200 | 8,680.50 | 38.80 | 0.45% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |